Dr. Reddys Laboratories Ltd.

Dr. Reddy’s Laboratories is currently trading at Rs. 3187.00, up by 2.60 points or 0.08% from its previous closing of Rs. 3184.40 on the BSE.

The scrip opened at Rs. 3194.95 and has touched a high and low of Rs. 3219.00 and Rs. 3182.60 respectively. So far 35,370 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4382.95 on 20-Oct-2015 and a 52 week low of Rs. 2750.00 on 21-Jan-2016.

Last one week high and low of the scrip stood at Rs. 3219.00 and Rs. 3053.35 respectively. The current market cap of the company is Rs. 54,317.00 crore.

The promoters holding in the company stood at 25.58%, while Institutions and Non-Institutions held 42.02% and 32.40% respectively.

Dr. Reddy’s Laboratories’ US subsidiary -- Promius Pharma -- has launched Sernivo (betamethasone dipropionate) Spray, 0.05% in the U.S. Sernivo Spray, a prescription topical steroid approved by the Food and Drug Administration (FDA) in February of 2016, is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older.

Promius has conducted two multi-center, randomized, double-blind, vehicle-controlled clinical trials in subjects aged 18 years and older with moderate plaque psoriasis to evaluate the safety and efficacy of Sernivo Spray. In both trials, randomized subjects applied Sernivo Spray or vehicle spray to the affected areas twice daily for 28 days.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas.